This is just the sort of publicity HDII needs
(my bolding)
>>>>>>>>>>>>
Friday February 16, 11:48 am Eastern Time
Press Release
SOURCE: Hypertension Diagnostics, Inc.
Hypertension Diagnostics Featured in The Wall Street Transcript
ST. PAUL, Minn., Feb. 16 /PRNewswire/ --Hypertension Diagnostics, Inc. (Nasdaq: HDII; HDIIW; HDIIU), said today that the company was recently featured in a CEO Interview profile published in The Wall Street Transcript.
In the Jan. 22, 2001 issue of The Wall Street Transcript (``TWST''), a five page interview with Greg H. Guettler, President, and James S. Murphy, Senior Vice President, Finance and Administration and Chief Financial Officer, was published. Using a question and answer format, a wide range of subjects relating to Hypertension Diagnostics were covered including the history and overview of HDI's business, information about the HDI/PulseWave(TM) CR-2000 research and CVProfilor(TM) DO-2020 physician products, the markets and marketing plans for these CardioVascular Profiling Systems, reimbursement regarding tests using the CVProfilor(TM) DO-2020 System, and future milestones for investors to anticipate. When asked by the TWST interviewer for reasons why potential investors might consider buying HDI stock, Mr. Guettler responded that HDI has a fully developed, patented, scientifically validated and FDA cleared medical technology with a sizeable market opportunity involving payers and consumers all of whom seem to be embracing cardiovascular disease prevention. The CVProfiler(TM) System is able to address this concern by non-invasively screening patients in doctor's offices to determine if they have potential underlying vascular disease that might require more specific diagnostic evaluation by their physician.
<abridged>
<<<<<<<<<<<<<<<
biz.yahoo.com |
